{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "e72140308a847c441dd580d774848824",
    "title": "Morgan Stanley | RESEARCH",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/MS/Kyverna Therapeutics Highlights From Virtual KOL Event on Neuroimmunology CAR-T FranchiseKyverna Therapeutics Highlights_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:28:32.705793",
      "extracted_at": "2025-10-26T12:28:32.705811"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 11,
        "successful_pages": 11,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/MS",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 3,
          "removed_paragraphs": 2,
          "reduction_ratio": 0.13060886093866908
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/MS"
      }
    }
  },
  "passages": [
    {
      "passage_id": "fca588f830cb2479",
      "text": "August 28, 2025 07:58 PM GMT",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2e5987802c8eef8f",
      "text": "KOL event highlights positive, longer term data for KYY 101, provides details on the innovative Ph3 trial design in MG and lays out initial framework for the SPS and MG commercial strategy.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f73c4512b3423a13",
      "text": "- Updated KYY-101 data indicate continued durable, drug free and disease-free remission in SPS ( \\(>23\\) mo) and MG ( \\(>24\\) mo).- Innovative Ph3 study in MG supports a rapid and clear path to regulatory filing with a study of only 60 patients that's well powered for superiority.- Commercial strategy supports rapid and efficient launch in MG, while SPS represent first to market opportunity that may be larger than initially expected.- Reiterated interim Ph2 data in MG are expected in 4Q25 and pivotal Ph2 data in SPS are expected in 1H26.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1b5e564c697da0bf",
      "text": "Ph3 KYSA- 6 trial design in MG unveiled. Earlier today, Kyverna hosted a virtual KOL event (press release and presentation) where the company shared details of its Ph2/3 registrational design in myasthenia gravis (MG; Exhibit 1). Recall, after alignment with the FDA, the company amended its ongoing Ph2 KYSA- 6 trial into a Ph2/3 registrational study, which is expected to begin enrolling by YE25. The Ph2/3 KYSA- 6 trial ( \\(n = 60\\) ) is an open- label, randomized, controlled study seeking to demonstrate superiority of KYY- 101 compared to standard of care (SOC; traditional agents or complement pathway inhibitors). The co- primary endpoints are a change from baseline in Myasthenia Gravis- Activities of Daily Living (MG- ADL) and Quantitative Myasthenia Gravis (QMG) scores at 24 weeks compared to the SOC treatment arm. Key Secondary endpoints include change from baseline in Myasthenia Gravis Composite (MGC) score at 24 weeks compared to the SOC treatment arm and patients initially randomized to standard of care will have the option crossover and receive KYY- 101. Mgt. reiterated plans to report data from the Ph2 portion of KYSA- 6 in 4Q25 (Exhibit 2), where they plan to share data from 6 patients with up to 9 months of follow up.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3125359ef3d1318e",
      "text": "KYV- 101 value proposition can change treatment paradigm in SPS and MG. Mgt. reviewed longer- term data from KYY- 101 compassionate use treated patients in SPS and MG, which showed drug free and disease free remission out to \\(\\sim 2\\) years, highlighting durability with a single treatment. Meanwhile on safety, the company highlighted it recently treated the 100th patient with KYY- 101, continuing to build the encouraging safety database. On the treatment paradigm, there continues to be",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "e85c0d7aaabd4c96",
      "text": "Biotechnology | United States of AmericaStock RatingOverweightIndustry ViewAttractivePrice target$20.00Shr price, close (Aug 27, 2025)$3.69Mkt cap, curr (mm)$15952-Week Range$8.32-1.78",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "43c9779d7714ed7c",
      "text": "Fiscal Year Ending12/2412/25e12/26e12/27eEPS ($)**(3.33)(4.06)(4.17)(4.36)Prior EPS ($)**----P/ENMNMNMNMEPS ($)(3.30)(3.81)(3.59)(3.70)Div yld (%)----",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "995591cd241a7d24",
      "text": "Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework \\\\*\\\\* = Based on consensus methodology \\(\\S =\\) Consensus data is provided by Refinitiv Estimates e = Morgan Stanley Research estimates",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "8add7de8bf11ebb4",
      "text": "Quarter20242025e Prior Current2025e Prior Current2026e Prior CurrentQ1(1.12)- (1.03)a--Q2(0.67)- (0.97)a--Q3(0.80)- (1.09)--Q4(0.87)- (1.13)--",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "057567370b0c6073",
      "text": "e = Morgan Stanley Research estimates, a = Actual Company reported data",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "614fb86a4e549c60",
      "text": "Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c7df7dfb3ad4f5cd",
      "text": "For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1124d400396b3efb",
      "text": "a high unmet need in both autoimmune diseases (SPS and MG), with no currently approved treatments on the market for SPS and MG patients relying on suboptimal, expensive and chronic therapies. The KOLs agreed CAR- T cell therapy in autoimmune diseases has the potential to evolve and be used in earlier lines of therapy once there is enough data available.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "26f4193cc38cf0d3",
      "text": "SPS commercial opportunity larger than initially estimated. Mgt. highlighted the company's commercialization strategy for the neuroimmunology franchise (Exhibit 3), supported by a first mover advantage in SPS and a subsequent synergistic launch in MG. Admittedly, the company believes the KYY- 101 addressable market in SPS was likely underestimated (previously 2- 2.5k patients) and now believes \\(\\sim 5.5k\\) patients ( \\(\\sim 90\\%\\) of total diagnosed) seek symptomatic treatments for the disease and can be addressable. Additionally, MG is a large market that continues to grow with increased awareness and adoption of new therapies and the company believes 40k patients (50% of the \\(\\sim 80k\\) patients with seropositive generalized MG) have an inadequate response to immunosuppressants. Kyverna plans to run a lean commercial model and target \\(\\sim 10\\) treatment centers once launched in SPS, further expanding to \\(\\sim 50 - 75\\) centers post approval in MG.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0c8456e700715162",
      "text": "Exhibit 1: Ph2/3 KYSA-6 Trial Design",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "39daf32efd46a25b",
      "text": "Source: Company Presentation",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "12afb1d6a7548232",
      "text": "Exhibit 2: Upcoming Catalysts",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "6ea25462ebe3dfcc",
      "text": "Source: Company Presentation",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f9c0e5ec27b48187",
      "text": "Exhibit 3: KTV- 101 Overall Commercial Opportunity in Neighbourhood",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a10c92b2624474f1",
      "text": "Uniquely positioned to be the FIRST to launch a CAR T- cell therapy for autoimmune diseases",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4d03abffe3ed9fd7",
      "text": "Our PT is derived from a discounted cash flow analysis that assumes a \\(15\\%\\) discount rate and \\(1\\%\\) terminal growth until 2035E.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "13c3d9b70e185ad7",
      "text": "- KYV-101 shows robust tolerability in autoimmune diseases- KYV-101 shows superior efficacy to competitors in autoimmune diseases- KYV-101 obtains FDA approval- KYV-101 gets to market faster than competitors",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9035b99160f031a9",
      "text": "- CAR-T therapy is not safe in autoimmune diseases- Competing CAR-T therapies show superior efficacy- Competing CAR-T therapies are first to market- KYV-101 does not obtain FDA approval",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9bdc74c3c98bbf22",
      "text": "The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, Morgan Stanley includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "cafa0e53355678b2",
      "text": "For mportant dislures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "bf629fb9155241db",
      "text": "For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303- 2495; Hong Kong +852 2848- 5999; Latin America +1 718 754- 5444 (U.S.); London +44 (0)20- 7425- 8169; Singapore +65 6834- 6860; Sydney +61 (0)2- 9770- 1505; Tokyo +81 (0)3- 6836- 9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "c610e7e4a60986d1",
      "text": "Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict policies. A Portuguese version of the policy can be found at www.morganstanley.com.br",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "4d3d738524ec7f1d",
      "text": "As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: 4D Molecular Therapeutics Inc, Acadia Pharmaceuticals Inc, Akero Therapeutics Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Arctis Biotherapeutics, Inc, aregenx SE, Arrowhead Pharmaceuticals Inc, Arvinas Inc, Ascendis Pharma A/S, Axsome Therapeutics, Bicycle Therapeutics Plc, Biogen Inc, Biomarin Pharmaceutical Inc, C4 Therapeutics, Cabaletta Bio Inc, Centessa Pharmaceuticals, Inc, Certara Inc, CG Oncology, Cytokinetics Inc, Denali Therapeutics Inc, Dyne Therapeutics Inc, Exelixis Inc, Galapagos NV, Genmab A/S, Gilead Sciences Inc, Halozyme Therapeutics, Inc, Incyte Corp, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, Mirum Pharmaceuticals, Moderna Inc, Neurocrine Biosciences Inc, Nurix Therapeutics Inc, ProKiney Corp, Recursion Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Regenxbio Inc, Rocket Pharmaceuticals Inc, Sarepta Therapeutics Inc, Schrodinger Inc, Silence Therapeutics Plc, Structure Therapeutics Inc, Trevi Therapeutics Inc, Tscan Therapeutics Inc, Vertex Pharmaceuticals, Viking Therapeutics Inc, Vir Biotechnology Inc, Zentalis Pharmaceuticals Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "9c45c7a3f0e6b32a",
      "text": "Within the last 12 months, Morgan Stanley managed or co- managed a public offering (or 144A of offerings) of securities of Aardvark Therapeutics Inc, ABSCI CORP, Akero Therapeutics Inc, Ascendis Pharma A/S, Bicara Therapeutics, BioAge Labs Inc, Biogen Inc, Biohaven Ltd, CG Oncology, Cricntes Pharmaceuticals, Dyne Therapeutics Inc, Gilead Sciences Inc, Ionis Pharmaceuticals Inc, Kymera Therapeutics Inc, Pharvaris NV, Rhythm Pharmaceuticals Inc, Roche Pharmaceuticals Inc, Sana Biotechnology, Inc, Sarepta Therapeutics Inc, Trevi Therapeutics Inc, Zenas Biopharma Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3a49a2f2f1bc1ce6",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Aardvark Therapeutics Inc, ABSCI CORP, Akero Therapeutics Inc, Alumis Inc, Ascendis Pharma A/S, Bicara Therapeutics, BioAge Labs Inc, Biogen Inc, Biohaven Ltd, CG Oncology, Contineum Therapeutics, Cricntes Pharmaceuticals, Dyne Therapeutics Inc, Genmab A/S, Gilead Sciences Inc, Ionis Pharmaceuticals Inc, Kymera Therapeutics Inc, Pharvaris NV, Rhythm Pharmaceuticals Inc, Roche Pharmaceuticals Inc, Sana Biotechnology, Inc, Sarepta Therapeutics Inc, Trevi Therapeutics Inc, Zenas Biopharma Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a03df1245a50ef8f",
      "text": "In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Aardvark Therapeutics Inc, Abivax, ABSCI CORP, Acadia Pharmaceuticals Inc, Adagene Inc, Akero Therapeutics Inc, Alcaterv Inc, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Arctis Biotherapeutics, Inc, aregenx SE, Arvinas Inc, Ascendis Pharma A/S, Axsome Therapeutics, BeOne Medicines, Bicara Therapeutics, BioAge Labs Inc, Biogen Inc, Biohaven Ltd, CG Oncology, Cricntes Pharmaceuticals, Dyne Therapeutics Inc, Gilead Sciences Inc, Ionis Pharmaceuticals Inc, Ldt, Biomarin Pharmaceutical Inc, BioNTech SE, Centessa Pharmaceuticals Inc, Certara Inc, CG Oncology, Compass Pathways PLC, Contineum Therapeutics, Cricntes Pharmaceuticals, Cricntes Pharmaceuticals, Cricntes Pharmaceuticals, Cricntes Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a64ea84850cc12f5",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Amgen Inc, BeOne Medicines, Biogen Inc, Certara Inc, Genmab A/S, Gilead Sciences Inc, Incyte Corp, Moderna Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "b8ffedaa96a45bc8",
      "text": "Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Aardvark Therapeutics Inc, Abivax, ABSCI CORP, Acadia Pharmaceuticals Inc, Adagene Inc, Akero Therapeutics Inc, Alcaterv Inc, Alnylam Pharmaceuticals Inc, Alumis Inc, Amgen Inc, Amicus Therapeutics Inc, Apellis Pharmaceuticals Inc, Arcus Biosciences Inc, Arcus Biotherapeutics, Inc, aregenx SE, Arvinas Inc, Ascendis Pharma A/S, Axsome Therapeutics, BeOne Medicines, Bicara Therapeutics, BioAge Labs Inc, Biogen Inc, Biohaven Ltd, Biomarin Pharmaceutical Inc, BioNTech SE, Centessa Pharmaceuticals, Inc, Certara Inc, CG Oncology, Compass Pathways PLC, Contineum Therapeutics, Cricntes Pharmaceuticals, Cricntes Pharmaceuticals, Cricntes Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc, Centessa Pharmaceuticals, Inc.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "e66bf70687675e27",
      "text": "Within the last 12 months, Morgan Stanley has either provided or is providing non- investment banking, securities- related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Amgen Inc, BeOne Medicines, Biogen Inc, BioNTech SE, Certara Inc, Cytokinetics Inc, Genmab A/S, Gilead Sciences Inc, Incyte Corp, Moderna Inc, Vertex Pharmaceuticals.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f9ea44f31f413141",
      "text": "Morgan Stanley & Co. LLC makes a market in the securities of 4D Molecular Therapeutics Inc, Aardvark Therapeutics Inc, ABSCI CORP, Alcaterv Inc, Amgen Inc, Amicus Therapeutics Inc, Arcellx",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "157fca443d5be217",
      "text": "Inc, Arus Biosciences Inc, Arctis Biotherapeutics, Inc, Arrowhead Pharmaceuticals Inc, Arvina Inc, Bicycle Therapeutics Plc, Biohaven Ltd, C4 Therapeutics, Celldex Therapeutics Inc, Centessa Pharmaceuticals, Inc, Certara Inc, CG Oncology, Cricntics Pharmaceuticals, Cullinan Therapeutics, Cytokinetics Inc, Denali Therapeutics Inc, Disc Medicine Inc, Dyne Therapeutics Inc, Erasca, Inc, Immunocore Holdings Ltd, Insmed Inc, Intellia Therapeutics Inc, IO Biotech, Ionis Pharmaceuticals Inc, Kymera Therapeutics Inc, Kyverna Therapeutics, Mirum Pharmaceuticals, Nurix Therapeutics Inc, Prime Medicine Inc, ProKidney Corp, PTC Therapeutics, Regenxbio Inc, Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, Schrodinger Inc, Silence Therapeutics Plc, Ultragenyx Pharmaceutical Inc, United Therapeutics Corp, Vir Biotechnology Inc, Y-mABs Therapeutics Inc, Zentalis Pharmaceuticals Inc.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ce68c051d38ae71e",
      "text": "The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "45e4152e5291f8c3",
      "text": "Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "42adc5caaa49ae99",
      "text": "Certain disclosures listed above are also for compliance with applicable regulations in non- US jurisdictions.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c47cf1b427956cef",
      "text": "Morgan Stanley uses a relative rating system using terms such as Overweight, Equal- weight, Not- Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ebed6c9545158ccd",
      "text": "(as of July 31, 2025)",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "ce33523d8ba67b0f",
      "text": "The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal- weight, Not- Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal- weight and Not- Rated to hold and Underweight to sell recommendations, respectively.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "049e32476f243cec",
      "text": "Coverage UniverseInvestment Banking Clients (IBC)Other Material Investment Services Clients (MISC)Count% of TotalCount% of Total IBC% of Rating CategoryCountStock Rating Category% of Total Other MISCOverweight/Buy149540%37845%25%701Equal-weight/Hold160743%37445%23%766Not-Rated/Hold50%00%0%2Underweight/Sell58816%8310%14%236Total3,6958351705",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "aa8eeda18bf1ece4",
      "text": "Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the % of total' column may not add up to exactly 100 percent.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1d2a1c90b4c04175",
      "text": "Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "746b3671376e5f32",
      "text": "Equal- weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "dfefe96d597c8e43",
      "text": "Not- Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "54289b9b456a1e08",
      "text": "Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12- 18 months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f862100c5205b07a",
      "text": "Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "33ef157a44544af1",
      "text": "Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12- 18 months to be attractive vs. the relevant broad market benchmark, as indicated below.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "0a6d71f6fa2158f4",
      "text": "In- Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12- 18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12- 18 months with caution vs. the relevant broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub- regional index or MSCI AC Asia Pacific ex Japan Index.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "72133ce2bad2a3fc",
      "text": "Morgan Stanley Research policy is to update research reports and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "f85a86ba27ba1bf5",
      "text": "Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd- Frank Wall Street Reform and Consumer Protection Act.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "2c778edb51ebfeb3",
      "text": "Morgan Stanley produces an equity research product called a \"Tactical Idea.\" Views contained in a Tactical Idea\" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "52b15b96c85c741c",
      "text": "Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third- party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "cbf2d9215315518b",
      "text": "Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "65a4571a2b31235e",
      "text": "in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b584a132cdeac7cf",
      "text": "The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts, strategists or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "b32bbb6a20314bb6",
      "text": "The \"Important Regulatory Disclosures on Subject Companies\" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns \\(1\\%\\) or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than \\(1\\%\\) in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "08f296116425225e",
      "text": "With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "6b51da9eb3a953bb",
      "text": "Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre- approved by authorized members of Research management.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "24b76050d04b5f94",
      "text": "Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "35e8093ed67dd990",
      "text": "To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited (\"MSTL\"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non- customer reader within the scope of Article 7- 1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bab0a1561b9b0815",
      "text": "Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bdb793a678c90ccd",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "a6a52085ecda8cb9",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "edb85e74a5aad4da",
      "text": "As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "83804a6cda807383",
      "text": "The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "068812079996518c",
      "text": "Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework. The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "81e0e5b34a0fdacc",
      "text": "Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "ac76a721064210ec",
      "text": "COMPANY (TICKER)RATING (AS OF)PRICE* (08/27/2025)Judah C. Frommer, CFA4D Molecular Therapeutics Inc (FDMT.O)U (11/21/2024)$6.46Abivax (ABVX.O)O (07/23/2025)$79.43Apellis Pharmaceuticals Inc (APLS.O)E (11/21/2024)$28.22Arcelix Inc (ACLX.O)O (03/07/2024)$69.90Arcutis Biotherapeutics, Inc. (ARQT.O)O (07/02/2025)$15.65Bicara Therapeutics (BCAX.O)O (10/08/2024)$12.02Celldex Therapeutics Inc (CLDX.O)O (03/20/2025)$22.60Compass Pathways PLC (CMPS.O)O (08/08/2025)$4.72enGene Holdings Inc. (ENGN.O)O (03/08/2024)$4.34Galapagos NV (GLPG.O)U (02/13/2025)$32.91Genmab A/S (GMAB.O)E (07/02/2025)$24.78Incyte Corp (INCY.O)E (07/02/2025)$84.84Kymera Therapeutics Inc (KYMR.O)O (07/02/2025)$42.26Mural Oncology (MURA.O)E (03/25/2025)$2.06ProKidney Corp (PROK.O)E (11/10/2022)$2.49PTC Therapeutics (PTCT.O)O (03/06/2025)$49.78Regenxbio Inc (RGNX.O)O (11/15/2024)$8.82Trevi Therapeutics Inc (TRVI.O)O (08/21/2025)$8.00Zenas Biopharma Inc (ZBIO.O)O (07/02/2025)$16.71Maxwell SkorAdagene Inc. (ADAG.O)E (01/30/2025)$2.19Amicus Therapeutics Inc. (FOLD.O)O (07/16/2025)$7.64Ascendis Pharma A/S (ASND.O)O (05/05/2025)$193.01Atea Pharmaceuticals Inc (AVIR.O)E (08/12/2024)$3.60Bicycle Therapeutics Plc (BCYC.O)E (02/14/2022)$7.00Crinetics Pharmaceuticals (CRNX.O)O (01/16/2024)$30.40Cytokinetics Inc (CYTK.O)O (02/13/2025)$37.83Inspired Inc (INSM.O)E (08/12/2025)$134.53Pharvaris N.V. (PHVS.O)O (08/15/2023)$23.78Sana Biotechnology, Inc (SANA.O)O (03/01/2021)$3.37Tscan Therapeutics Inc (TCRX.O)O (03/13/2025)$1.87Ultragenyx Pharmaceutical Inc (RARE.O)O (03/27/2019)$30.08",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "cd4ca6a05c03e47e",
      "text": "Aardvark Therapeutics Inc. (AARD.O)O (03/10/2025)$8.99Akero Therapeutics Inc (AKRO.O)O (01/27/2023)$48.19Alnylam Pharmaceuticals Inc (ALNY.O)E (09/09/2022)$454.18Arrowhead Pharmaceuticals Inc (ARWR.O)E (09/09/2022)$21.79BioAge Labs Inc (BIOA.O)U (12/09/2024)$4.74Cabaletta Bio Inc (CABA.O)O (01/27/2023)$1.50Dyne Therapeutics Inc (DYN.O)O (04/30/2024)$13.64Fractyl Health Inc (GUTS.O)O (02/27/2024)$0.99IO Biotech (IOBT.O)O (11/30/2021)$1.68Ionis Pharmaceuticals Inc (IONS.O)O (07/30/2025)$42.75Kyverna Therapeutics (KYTX.O)O (03/04/2024)$3.69Mirum Pharmaceuticals (MIRM.O)O (11/13/2023)$74.65Rhythm Pharmaceuticals Inc (RYTM.O)O (12/19/2023)$102.30Rocket Pharmaceuticals Inc (RCKT.O)E (05/27/2025)$3.32Sarepta Therapeutics Inc (SRPT.O)E (06/16/2025)$18.07Silence Therapeutics Plc (SLN.O)O (05/08/2023)$5.20Tenaya Therapeutics Inc (TNYA.O)O (08/24/2021)$1.10Viking Therapeutics Inc (VKTX.O)O (06/27/2024)$26.62Vir Biotechnology Inc (VIR.O)O (01/08/2025)$5.23Y-mABs Therapeutics Inc. (YMAB.O)E (08/05/2025)$8.55Zentalis Pharmaceuticals Inc (ZNTL.O)E (06/18/2024)$1.82Sean Laaman, Ph.D.ABSCI CORP (ABSI.O)O (07/03/2024)$2.55Acadia Pharmaceuticals Inc (ACAD.O)E (08/06/2024)$26.57Alector Inc (ALEC.O)U (11/26/2024)$2.40argenx SE (ARGX.O)O (07/02/2025)$707.96Axsome Therapeutics (AXSM.O)O (04/29/2024)$121.86BeOne Medicines (ONC.O)O (12/02/2024)$300.14Biomarin Pharmaceutical Inc (BMRN.O)O (07/02/2025)$58.66Centessa Pharmaceuticals, Inc (CNTA.O)O (09/19/2024)$16.65Certara Inc (CERT.O)E (01/05/2021)$10.97CG Oncology (CGON.O)O (02/19/2024)$26.48Contineum Therapeutics (CTNM.O)O (04/30/2024)$10.01Cullinan Therapeutics (CGEM.O)O (03/06/2025)$7.93Denali Therapeutics Inc (DNLI.O)O (03/06/2025)$15.60Disc Medicine Inc (IRON.O)O (11/04/2024)$59.95Erasca, Inc. (ERAS.O)E (08/17/2025)$1.58Exelixis Inc. (EXEL.O)O (01/26/2025)$38.51Halozyme Therapeutics, Inc (HALO.O)O (08/05/2025)$73.18Immunocore Holdings Ltd (IMCR.O)E (12/12/2024)$32.65Neurocrine Biosciences Inc (NBIX.O)O (03/06/2025)$138.13Recursion Pharmaceuticals Inc (RXRX.O)E (05/22/2023)$4.89Schrodinger Inc. (SDGR.O)E (11/19/2021)$19.79Terence C Flynn, Ph.D.Alumis Inc. (ALMS.O)O (05/30/2025)$4.92Amgen Inc. (AMGN.O)E (10/16/2023)$287.97Arcus Biosciences Inc. (RCUS.N)O (10/11/2022)$10.56Arvinas Inc (ARVN.O)E (04/06/2022)$8.08Biogen Inc (BIIB.O)E (10/31/2024)$136.36Biohaven Ltd (BHVN.N)O (07/24/2024)$15.60BioNTech SE (BNTX.O)O (09/23/2024)$103.01C4 Therapeutics (CCCC.O)E (11/06/2023)$2.58CRISPR Therapeutics AG (CRSP.O)U (10/11/2022)$53.53Gilead Sciences Inc. (GILD.O)O (01/10/2025)$113.92Intellia Therapeutics Inc (NTLA.O)E (01/26/2025)$11.42",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8945c7ac74ea0801",
      "text": "Legend Biotech Corp (LEGN.O)O (01/31/2022)$34.72Moderna Inc (MRNA.O)E (12/16/2020)$25.10Nurix Therapeutics Inc. (NRIX.O)E (10/11/2022)$9.55Prime Medicine Inc (PRME.O)E (11/14/2022)$3.43Regeneron Pharmaceuticals Inc. (REGN.O)O (09/09/2022)$586.96Structure Therapeutics Inc (GPCR.O)O (09/22/2024)$19.00United Therapeutics Corp (UTHR.O)E (07/11/2024)$305.35Vertex Pharmaceuticals (VRTX.O)E (05/03/2022)$389.08",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "604dda9414260b22",
      "text": "Stock Ratings are subject to change. Please see latest research for each company.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "adb5aef038e9cdb2",
      "text": "* Historical prices are not split adjusted.",
      "page": 10,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "5dc8f59a60c48918",
      "name": "ADGM Branch",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "394218ab3d61ca43",
      "name": "Aardvark Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f443b8b74e05708c",
      "name": "Aardvark Therapeutics Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ed49291dd8535b70",
      "name": "Abu Dhabi",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7a8acf40cea751b9",
      "name": "Acadia Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6a2ad8c9a1d57a63",
      "name": "Acadia Pharmaceuticals Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3c8d4c9b95a10ee1",
      "name": "Actual Company",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ad3baf6ab633d43b",
      "name": "Adagene Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5116c8ebe3678cc0",
      "name": "Akero Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f3b6b3f250f42fb9",
      "name": "Akero Therapeutics Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "caec7e5b3b10450f",
      "name": "Alcaterv Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e970e25f5b33fddb",
      "name": "Alector Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ce2ccb36242da64f",
      "name": "Alnylam Pharmaceuticals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "65911636744ff4ec",
      "name": "Alnylam Pharmaceuticals Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9612cce96a083c31",
      "name": "Alumis Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a9935cd77e910646",
      "name": "America Index",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "aa4b9a172f427744",
      "name": "Amgen Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6823ccc624fd5def",
      "name": "Amicus Therapeutics",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6fb1a9d53df3c6c4",
      "name": "Amicus Therapeutics Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e8600890357193e9",
      "name": "Analyst Industry",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": "~60-patient, global, open-label, randomized controlled Phase 2/3 trial with crossover design",
        "page": 2,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Baseline Measurement",
              "24 weeks",
              "18 Months"
            ]
          },
          "y": {
            "unit": null,
            "range": null
          }
        },
        "series": [
          {
            "name": "Trial Design",
            "unit": null,
            "values": [
              {
                "stage": "Screening, washout, apheresis, and resume standard of care",
                "time_point": "Start"
              },
              {
                "stage": "Randomized (N=~60, 1:1)",
                "time_point": "Baseline Measurement"
              },
              {
                "arm": "KYV-101",
                "details": "Cyc/Flu lymphodepletion + Single infusion of 1x10^8 CAR T cells",
                "duration": "24 weeks"
              },
              {
                "arm": "Standard of Care",
                "details": "Traditional agents or complement pathway inhibitors",
                "duration": "24 weeks"
              },
              {
                "stage": "Co-Primary Endpoints (MG-ADL & QMG)",
                "time_point": "24 weeks"
              },
              {
                "arm": "KYV-101",
                "stage": "Follow Up",
                "time_point": "After 24 weeks"
              },
              {
                "arm": "Standard of Care",
                "stage": "KYV-101 Crossover",
                "time_point": "After 24 weeks"
              },
              {
                "arm": "Standard of Care (Crossover)",
                "stage": "Follow Up",
                "time_point": "After Crossover"
              },
              {
                "stage": "End of trial",
                "time_point": "18 Months"
              }
            ]
          }
        ],
        "figure_id": "062f02ab6537462d",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "table",
        "title": null,
        "page": 2,
        "axes": null,
        "series": [
          {
            "name": "Stiff Person Syndrome",
            "unit": null,
            "values": [
              "Complete Pivotal Phase 2 Enrollment mid-2025",
              "Report Topline Pivotal Phase 2 Data 1H 2026",
              "BLA filing in 1H 2026"
            ]
          },
          {
            "name": "Myasthenia Gravis",
            "unit": null,
            "values": [
              "Confirm Registrational Path with Regulators 1H 2025",
              "Report Interim Phase 2 Data Q4 2025",
              "Initiate Patient Enrollment for Phase 3 Registrational Trial by Year-End 2025"
            ]
          },
          {
            "name": "Additional Indications",
            "unit": null,
            "values": [
              "MS: Report Phase 1 IIT Data Q3 2025",
              "RA: Report Phase 1/2 IIT Data Q4 2025",
              "LN: Report Phase 1 Data in a Peer-Reviewed Publication in 2026"
            ]
          },
          {
            "name": "Future Pipeline",
            "unit": null,
            "values": [
              "File KYV-102 IND Application Q4 2025"
            ]
          }
        ],
        "figure_id": "8f1e5b253b1cfc89",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 3,
        "axes": null,
        "series": [
          {
            "name": "Key Points",
            "unit": null,
            "values": [
              "Significant KYV-101 addressable market in both SPS and MG",
              "SPS: Set a new treatment standard as first FDA-approved therapy",
              "MG: Change the treatment paradigm in large, growing market",
              "Opportunity for KYV-101 given current treatment options have high cost-burden and suboptimal outcomes",
              "Commercial strategy to build efficient and scalable neuroimmunology franchise; first-mover advantage in SPS will enable rapid market entry and uptake in MG",
              "CAR-T ecosystem has rapidly evolved setting up a successful launch environment for KYV-101"
            ]
          }
        ],
        "figure_id": "de6d0e93961bb494",
        "provenance": {
          "page": 3
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "464c8ace06fb3f22",
        "value": 20.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "y View</td><td></td><td></td><td>Attractive</td></tr><tr><td>Price target</td><td></td><td></td><td>$20.00</td></tr><tr><td>Shr price, close (Aug 27, 2025)</td><td></td><td></td><td>$3.69</td></tr><tr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "59d66477051fc28b",
        "value": 3.69,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td></td><td>$20.00</td></tr><tr><td>Shr price, close (Aug 27, 2025)</td><td></td><td></td><td>$3.69</td></tr><tr><td>Mkt cap, curr (mm)</td><td></td><td></td><td>$159</td></tr><tr><td>52-Week Ra",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f89d92fd87512f22",
        "value": 159.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2025)</td><td></td><td></td><td>$3.69</td></tr><tr><td>Mkt cap, curr (mm)</td><td></td><td></td><td>$159</td></tr><tr><td>52-Week Range</td><td></td><td></td><td>$8.32-1.78</td></tr></table> <table><t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "a2ab2381601fc9a1",
        "value": 8.32,
        "unit": "$",
        "metric_type": "currency",
        "context": ", curr (mm)</td><td></td><td></td><td>$159</td></tr><tr><td>52-Week Range</td><td></td><td></td><td>$8.32-1.78</td></tr></table> <table><tr><td>Fiscal Year Ending</td><td>12/24</td><td>12/25e</td><td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "66aaf466b628e828",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "grow with increased awareness and adoption of new therapies and the company believes 40k patients (50% of the \\(\\sim 80k\\) patients with seropositive generalized MG) have an inadequate response to imm",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "0629c51a612be021",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Regulatory Disclosures on Subject Companies As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanle",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "a895e8a4aed7d0fb",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td></td><td></td><td>% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td></tr><tr><td>Equal-weight/Hold</td><td>1607<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "fe56f15a0cb06549",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "4a84da5476ee95d2",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "80e2c9e8d2ac49cc",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>378</td><td>45%</td><td>25%</td><td>701</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3daa1b2c502ba70a",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>25%</td><td>701</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "2bdd2cb37699f001",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>701</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "4bf072ead5144aeb",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>374</td><td>45%</td><td>23%</td><td>766</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3e45dd4743d520bb",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">45%</td><td>23%</td><td>766</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ba3cf0cfeb0394db",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>23%</td><td>766</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "42799451021e7c52",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td></tr><tr><td>Total</td><td>3,695</td><td></td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6f61bc6b0f6f4e0d",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>0%</td><td>2</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "bf128ff591e9b6f4",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>2</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><td>1705</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "991862ebb260b69b",
        "value": 6.46,
        "unit": "$",
        "metric_type": "currency",
        "context": "td></td><td></td></tr><tr><td>4D Molecular Therapeutics Inc (FDMT.O)</td><td>U (11/21/2024)</td><td>$6.46</td></tr><tr><td>Abivax (ABVX.O)</td><td>O (07/23/2025)</td><td>$79.43</td></tr><tr><td>Apelli",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "308382182f01f4af",
        "value": 79.43,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>U (11/21/2024)</td><td>$6.46</td></tr><tr><td>Abivax (ABVX.O)</td><td>O (07/23/2025)</td><td>$79.43</td></tr><tr><td>Apellis Pharmaceuticals Inc (APLS.O)</td><td>E (11/21/2024)</td><td>$28.22</",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7f403cee51253068",
        "value": 28.22,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$79.43</td></tr><tr><td>Apellis Pharmaceuticals Inc (APLS.O)</td><td>E (11/21/2024)</td><td>$28.22</td></tr><tr><td>Arcelix Inc (ACLX.O)</td><td>O (03/07/2024)</td><td>$69.90</td></tr><tr><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "1bb62d46b1562488",
        "value": 69.9,
        "unit": "$",
        "metric_type": "currency",
        "context": ">E (11/21/2024)</td><td>$28.22</td></tr><tr><td>Arcelix Inc (ACLX.O)</td><td>O (03/07/2024)</td><td>$69.90</td></tr><tr><td>Arcutis Biotherapeutics, Inc. (ARQT.O)</td><td>O (07/02/2025)</td><td>$15.65",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c76359d6c61dc7ad",
        "value": 15.65,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$69.90</td></tr><tr><td>Arcutis Biotherapeutics, Inc. (ARQT.O)</td><td>O (07/02/2025)</td><td>$15.65</td></tr><tr><td>Bicara Therapeutics (BCAX.O)</td><td>O (10/08/2024)</td><td>$12.02</td></tr>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "18c5e719eaf4225b",
        "value": 12.02,
        "unit": "$",
        "metric_type": "currency",
        "context": "2/2025)</td><td>$15.65</td></tr><tr><td>Bicara Therapeutics (BCAX.O)</td><td>O (10/08/2024)</td><td>$12.02</td></tr><tr><td>Celldex Therapeutics Inc (CLDX.O)</td><td>O (03/20/2025)</td><td>$22.60</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "dee98cc6bd520cd1",
        "value": 22.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "4)</td><td>$12.02</td></tr><tr><td>Celldex Therapeutics Inc (CLDX.O)</td><td>O (03/20/2025)</td><td>$22.60</td></tr><tr><td>Compass Pathways PLC (CMPS.O)</td><td>O (08/08/2025)</td><td>$4.72</td></tr>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "c50f03aeae9d2627",
        "value": 4.72,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2025)</td><td>$22.60</td></tr><tr><td>Compass Pathways PLC (CMPS.O)</td><td>O (08/08/2025)</td><td>$4.72</td></tr><tr><td>enGene Holdings Inc. (ENGN.O)</td><td>O (03/08/2024)</td><td>$4.34</td></tr><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e5e1106f146c850b",
        "value": 4.34,
        "unit": "$",
        "metric_type": "currency",
        "context": "8/2025)</td><td>$4.72</td></tr><tr><td>enGene Holdings Inc. (ENGN.O)</td><td>O (03/08/2024)</td><td>$4.34</td></tr><tr><td>Galapagos NV (GLPG.O)</td><td>U (02/13/2025)</td><td>$32.91</td></tr><tr><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "eb145b2d89a4b5a0",
        "value": 32.91,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (03/08/2024)</td><td>$4.34</td></tr><tr><td>Galapagos NV (GLPG.O)</td><td>U (02/13/2025)</td><td>$32.91</td></tr><tr><td>Genmab A/S (GMAB.O)</td><td>E (07/02/2025)</td><td>$24.78</td></tr><tr><td>I",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7825ecd648330051",
        "value": 24.78,
        "unit": "$",
        "metric_type": "currency",
        "context": "d>U (02/13/2025)</td><td>$32.91</td></tr><tr><td>Genmab A/S (GMAB.O)</td><td>E (07/02/2025)</td><td>$24.78</td></tr><tr><td>Incyte Corp (INCY.O)</td><td>E (07/02/2025)</td><td>$84.84</td></tr><tr><td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "50b31e789a7ba58c",
        "value": 84.84,
        "unit": "$",
        "metric_type": "currency",
        "context": ">E (07/02/2025)</td><td>$24.78</td></tr><tr><td>Incyte Corp (INCY.O)</td><td>E (07/02/2025)</td><td>$84.84</td></tr><tr><td>Kymera Therapeutics Inc (KYMR.O)</td><td>O (07/02/2025)</td><td>$42.26</td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "63133923b5306099",
        "value": 42.26,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$84.84</td></tr><tr><td>Kymera Therapeutics Inc (KYMR.O)</td><td>O (07/02/2025)</td><td>$42.26</td></tr><tr><td>Mural Oncology (MURA.O)</td><td>E (03/25/2025)</td><td>$2.06</td></tr><tr><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "637b4fdac3047667",
        "value": 2.06,
        "unit": "$",
        "metric_type": "currency",
        "context": "(07/02/2025)</td><td>$42.26</td></tr><tr><td>Mural Oncology (MURA.O)</td><td>E (03/25/2025)</td><td>$2.06</td></tr><tr><td>ProKidney Corp (PROK.O)</td><td>E (11/10/2022)</td><td>$2.49</td></tr><tr><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "38052bc374da14f8",
        "value": 2.49,
        "unit": "$",
        "metric_type": "currency",
        "context": "(03/25/2025)</td><td>$2.06</td></tr><tr><td>ProKidney Corp (PROK.O)</td><td>E (11/10/2022)</td><td>$2.49</td></tr><tr><td>PTC Therapeutics (PTCT.O)</td><td>O (03/06/2025)</td><td>$49.78</td></tr><tr><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "586cb05fda7edde6",
        "value": 49.78,
        "unit": "$",
        "metric_type": "currency",
        "context": "11/10/2022)</td><td>$2.49</td></tr><tr><td>PTC Therapeutics (PTCT.O)</td><td>O (03/06/2025)</td><td>$49.78</td></tr><tr><td>Regenxbio Inc (RGNX.O)</td><td>O (11/15/2024)</td><td>$8.82</td></tr><tr><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e854382b02ddea21",
        "value": 8.82,
        "unit": "$",
        "metric_type": "currency",
        "context": "(03/06/2025)</td><td>$49.78</td></tr><tr><td>Regenxbio Inc (RGNX.O)</td><td>O (11/15/2024)</td><td>$8.82</td></tr><tr><td>Trevi Therapeutics Inc (TRVI.O)</td><td>O (08/21/2025)</td><td>$8.00</td></tr>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "fc89f57eea680e61",
        "value": 8.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "2024)</td><td>$8.82</td></tr><tr><td>Trevi Therapeutics Inc (TRVI.O)</td><td>O (08/21/2025)</td><td>$8.00</td></tr><tr><td>Zenas Biopharma Inc (ZBIO.O)</td><td>O (07/02/2025)</td><td>$16.71</td></tr><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "6c6122feb30a1fd3",
        "value": 16.71,
        "unit": "$",
        "metric_type": "currency",
        "context": "21/2025)</td><td>$8.00</td></tr><tr><td>Zenas Biopharma Inc (ZBIO.O)</td><td>O (07/02/2025)</td><td>$16.71</td></tr><tr><td>Maxwell Skor</td><td></td><td></td></tr><tr><td>Adagene Inc. (ADAG.O)</td><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "fbda8f4943ad2253",
        "value": 2.19,
        "unit": "$",
        "metric_type": "currency",
        "context": "axwell Skor</td><td></td><td></td></tr><tr><td>Adagene Inc. (ADAG.O)</td><td>E (01/30/2025)</td><td>$2.19</td></tr><tr><td>Amicus Therapeutics Inc. (FOLD.O)</td><td>O (07/16/2025)</td><td>$7.64</td></",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "a3239f51799b247d",
        "value": 7.64,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$2.19</td></tr><tr><td>Amicus Therapeutics Inc. (FOLD.O)</td><td>O (07/16/2025)</td><td>$7.64</td></tr><tr><td>Ascendis Pharma A/S (ASND.O)</td><td>O (05/05/2025)</td><td>$193.01</td></tr>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "559243f19da95b4b",
        "value": 193.01,
        "unit": "$",
        "metric_type": "currency",
        "context": "16/2025)</td><td>$7.64</td></tr><tr><td>Ascendis Pharma A/S (ASND.O)</td><td>O (05/05/2025)</td><td>$193.01</td></tr><tr><td>Atea Pharmaceuticals Inc (AVIR.O)</td><td>E (08/12/2024)</td><td>$3.60</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "23a6dd78e9887a88",
        "value": 3.6,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>$193.01</td></tr><tr><td>Atea Pharmaceuticals Inc (AVIR.O)</td><td>E (08/12/2024)</td><td>$3.60</td></tr><tr><td>Bicycle Therapeutics Plc (BCYC.O)</td><td>E (02/14/2022)</td><td>$7.00</td></",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "53efadd6dfb634eb",
        "value": 7.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "24)</td><td>$3.60</td></tr><tr><td>Bicycle Therapeutics Plc (BCYC.O)</td><td>E (02/14/2022)</td><td>$7.00</td></tr><tr><td>Crinetics Pharmaceuticals (CRNX.O)</td><td>O (01/16/2024)</td><td>$30.40</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f46f85aba472fc7a",
        "value": 30.4,
        "unit": "$",
        "metric_type": "currency",
        "context": "2)</td><td>$7.00</td></tr><tr><td>Crinetics Pharmaceuticals (CRNX.O)</td><td>O (01/16/2024)</td><td>$30.40</td></tr><tr><td>Cytokinetics Inc (CYTK.O)</td><td>O (02/13/2025)</td><td>$37.83</td></tr><tr",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "00c0fe36bd1416e6",
        "value": 37.83,
        "unit": "$",
        "metric_type": "currency",
        "context": "1/16/2024)</td><td>$30.40</td></tr><tr><td>Cytokinetics Inc (CYTK.O)</td><td>O (02/13/2025)</td><td>$37.83</td></tr><tr><td>Inspired Inc (INSM.O)</td><td>E (08/12/2025)</td><td>$134.53</td></tr><tr><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "a50b6744d442b816",
        "value": 134.53,
        "unit": "$",
        "metric_type": "currency",
        "context": "O (02/13/2025)</td><td>$37.83</td></tr><tr><td>Inspired Inc (INSM.O)</td><td>E (08/12/2025)</td><td>$134.53</td></tr><tr><td>Pharvaris N.V. (PHVS.O)</td><td>O (08/15/2023)</td><td>$23.78</td></tr><tr>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "89a8903c8dddda22",
        "value": 23.78,
        "unit": "$",
        "metric_type": "currency",
        "context": "08/12/2025)</td><td>$134.53</td></tr><tr><td>Pharvaris N.V. (PHVS.O)</td><td>O (08/15/2023)</td><td>$23.78</td></tr><tr><td>Sana Biotechnology, Inc (SANA.O)</td><td>O (03/01/2021)</td><td>$3.37</td></",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "a8b94a2a45dd6204",
        "value": 3.37,
        "unit": "$",
        "metric_type": "currency",
        "context": "23)</td><td>$23.78</td></tr><tr><td>Sana Biotechnology, Inc (SANA.O)</td><td>O (03/01/2021)</td><td>$3.37</td></tr><tr><td>Tscan Therapeutics Inc (TCRX.O)</td><td>O (03/13/2025)</td><td>$1.87</td></tr",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "e456f8dc93d62a7b",
        "value": 1.87,
        "unit": "$",
        "metric_type": "currency",
        "context": "2021)</td><td>$3.37</td></tr><tr><td>Tscan Therapeutics Inc (TCRX.O)</td><td>O (03/13/2025)</td><td>$1.87</td></tr><tr><td>Ultragenyx Pharmaceutical Inc (RARE.O)</td><td>O (03/27/2019)</td><td>$30.08<",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "be75ad60cd12e536",
        "value": 30.08,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$1.87</td></tr><tr><td>Ultragenyx Pharmaceutical Inc (RARE.O)</td><td>O (03/27/2019)</td><td>$30.08</td></tr></table> Michael E Ulz<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ccdc7a4074856f28",
        "value": 8.99,
        "unit": "$",
        "metric_type": "currency",
        "context": "<table><tr><td>Aardvark Therapeutics Inc. (AARD.O)</td><td>O (03/10/2025)</td><td>$8.99</td></tr><tr><td>Akero Therapeutics Inc (AKRO.O)</td><td>O (01/27/2023)</td><td>$48.19</td></tr><tr",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "6b6b610f9a45c334",
        "value": 48.19,
        "unit": "$",
        "metric_type": "currency",
        "context": "2025)</td><td>$8.99</td></tr><tr><td>Akero Therapeutics Inc (AKRO.O)</td><td>O (01/27/2023)</td><td>$48.19</td></tr><tr><td>Alnylam Pharmaceuticals Inc (ALNY.O)</td><td>E (09/09/2022)</td><td>$454.18<",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "4138bedbae813c57",
        "value": 454.18,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$48.19</td></tr><tr><td>Alnylam Pharmaceuticals Inc (ALNY.O)</td><td>E (09/09/2022)</td><td>$454.18</td></tr><tr><td>Arrowhead Pharmaceuticals Inc (ARWR.O)</td><td>E (09/09/2022)</td><td>$21.7",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ad0e98c378da0068",
        "value": 21.79,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>$454.18</td></tr><tr><td>Arrowhead Pharmaceuticals Inc (ARWR.O)</td><td>E (09/09/2022)</td><td>$21.79</td></tr><tr><td>BioAge Labs Inc (BIOA.O)</td><td>U (12/09/2024)</td><td>$4.74</td></tr><tr><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "c559a1eba0dacd3d",
        "value": 4.74,
        "unit": "$",
        "metric_type": "currency",
        "context": "09/09/2022)</td><td>$21.79</td></tr><tr><td>BioAge Labs Inc (BIOA.O)</td><td>U (12/09/2024)</td><td>$4.74</td></tr><tr><td>Cabaletta Bio Inc (CABA.O)</td><td>O (01/27/2023)</td><td>$1.50</td></tr><tr>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "bdfc06f879a83687",
        "value": 1.5,
        "unit": "$",
        "metric_type": "currency",
        "context": "2/09/2024)</td><td>$4.74</td></tr><tr><td>Cabaletta Bio Inc (CABA.O)</td><td>O (01/27/2023)</td><td>$1.50</td></tr><tr><td>Dyne Therapeutics Inc (DYN.O)</td><td>O (04/30/2024)</td><td>$13.64</td></tr>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "88e1558ce4154631",
        "value": 13.64,
        "unit": "$",
        "metric_type": "currency",
        "context": "7/2023)</td><td>$1.50</td></tr><tr><td>Dyne Therapeutics Inc (DYN.O)</td><td>O (04/30/2024)</td><td>$13.64</td></tr><tr><td>Fractyl Health Inc (GUTS.O)</td><td>O (02/27/2024)</td><td>$0.99</td></tr><t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "d85a934baaa3d25a",
        "value": 0.99,
        "unit": "$",
        "metric_type": "currency",
        "context": "30/2024)</td><td>$13.64</td></tr><tr><td>Fractyl Health Inc (GUTS.O)</td><td>O (02/27/2024)</td><td>$0.99</td></tr><tr><td>IO Biotech (IOBT.O)</td><td>O (11/30/2021)</td><td>$1.68</td></tr><tr><td>Ion",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "5f8c4ed7f0d8b843",
        "value": 1.68,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>O (02/27/2024)</td><td>$0.99</td></tr><tr><td>IO Biotech (IOBT.O)</td><td>O (11/30/2021)</td><td>$1.68</td></tr><tr><td>Ionis Pharmaceuticals Inc (IONS.O)</td><td>O (07/30/2025)</td><td>$42.75</td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "21825116580b6f2a",
        "value": 42.75,
        "unit": "$",
        "metric_type": "currency",
        "context": "1)</td><td>$1.68</td></tr><tr><td>Ionis Pharmaceuticals Inc (IONS.O)</td><td>O (07/30/2025)</td><td>$42.75</td></tr><tr><td>Kyverna Therapeutics (KYTX.O)</td><td>O (03/04/2024)</td><td>$3.69</td></tr>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7595386d0f31f98f",
        "value": 3.69,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2025)</td><td>$42.75</td></tr><tr><td>Kyverna Therapeutics (KYTX.O)</td><td>O (03/04/2024)</td><td>$3.69</td></tr><tr><td>Mirum Pharmaceuticals (MIRM.O)</td><td>O (11/13/2023)</td><td>$74.65</td></tr",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "62d9096091a19e89",
        "value": 74.65,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2024)</td><td>$3.69</td></tr><tr><td>Mirum Pharmaceuticals (MIRM.O)</td><td>O (11/13/2023)</td><td>$74.65</td></tr><tr><td>Rhythm Pharmaceuticals Inc (RYTM.O)</td><td>O (12/19/2023)</td><td>$102.30</",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "2e53947b098a5117",
        "value": 102.3,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$74.65</td></tr><tr><td>Rhythm Pharmaceuticals Inc (RYTM.O)</td><td>O (12/19/2023)</td><td>$102.30</td></tr><tr><td>Rocket Pharmaceuticals Inc (RCKT.O)</td><td>E (05/27/2025)</td><td>$3.32</t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ad0aa9e3c318ba6e",
        "value": 3.32,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$102.30</td></tr><tr><td>Rocket Pharmaceuticals Inc (RCKT.O)</td><td>E (05/27/2025)</td><td>$3.32</td></tr><tr><td>Sarepta Therapeutics Inc (SRPT.O)</td><td>E (06/16/2025)</td><td>$18.07</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "0d33bef794298631",
        "value": 18.07,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$3.32</td></tr><tr><td>Sarepta Therapeutics Inc (SRPT.O)</td><td>E (06/16/2025)</td><td>$18.07</td></tr><tr><td>Silence Therapeutics Plc (SLN.O)</td><td>O (05/08/2023)</td><td>$5.20</td></",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "0384ff84e2b35888",
        "value": 5.2,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$18.07</td></tr><tr><td>Silence Therapeutics Plc (SLN.O)</td><td>O (05/08/2023)</td><td>$5.20</td></tr><tr><td>Tenaya Therapeutics Inc (TNYA.O)</td><td>O (08/24/2021)</td><td>$1.10</td></t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "fe4d799e971d6b64",
        "value": 1.1,
        "unit": "$",
        "metric_type": "currency",
        "context": "023)</td><td>$5.20</td></tr><tr><td>Tenaya Therapeutics Inc (TNYA.O)</td><td>O (08/24/2021)</td><td>$1.10</td></tr><tr><td>Viking Therapeutics Inc (VKTX.O)</td><td>O (06/27/2024)</td><td>$26.62</td></",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "402cad11bac01a5b",
        "value": 26.62,
        "unit": "$",
        "metric_type": "currency",
        "context": "021)</td><td>$1.10</td></tr><tr><td>Viking Therapeutics Inc (VKTX.O)</td><td>O (06/27/2024)</td><td>$26.62</td></tr><tr><td>Vir Biotechnology Inc (VIR.O)</td><td>O (01/08/2025)</td><td>$5.23</td></tr>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ef17a9d74ec1aa3d",
        "value": 5.23,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2024)</td><td>$26.62</td></tr><tr><td>Vir Biotechnology Inc (VIR.O)</td><td>O (01/08/2025)</td><td>$5.23</td></tr><tr><td>Y-mABs Therapeutics Inc. (YMAB.O)</td><td>E (08/05/2025)</td><td>$8.55</td></",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "820d20bed2fbebdb",
        "value": 8.55,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$5.23</td></tr><tr><td>Y-mABs Therapeutics Inc. (YMAB.O)</td><td>E (08/05/2025)</td><td>$8.55</td></tr><tr><td>Zentalis Pharmaceuticals Inc (ZNTL.O)</td><td>E (06/18/2024)</td><td>$1.82</t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "bdb69c2f4921bf74",
        "value": 1.82,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$8.55</td></tr><tr><td>Zentalis Pharmaceuticals Inc (ZNTL.O)</td><td>E (06/18/2024)</td><td>$1.82</td></tr><tr><td>Sean Laaman, Ph.D.</td><td></td><td></td></tr><tr><td>ABSCI CORP (ABSI.O)</td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ff6a73d8578aa4d6",
        "value": 2.55,
        "unit": "$",
        "metric_type": "currency",
        "context": "Laaman, Ph.D.</td><td></td><td></td></tr><tr><td>ABSCI CORP (ABSI.O)</td><td>O (07/03/2024)</td><td>$2.55</td></tr><tr><td>Acadia Pharmaceuticals Inc (ACAD.O)</td><td>E (08/06/2024)</td><td>$26.57</td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7771a88c4ca3004a",
        "value": 26.57,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>$2.55</td></tr><tr><td>Acadia Pharmaceuticals Inc (ACAD.O)</td><td>E (08/06/2024)</td><td>$26.57</td></tr><tr><td>Alector Inc (ALEC.O)</td><td>U (11/26/2024)</td><td>$2.40</td></tr><tr><td>a",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ff0ce2fc7eb7d04c",
        "value": 2.4,
        "unit": "$",
        "metric_type": "currency",
        "context": ">E (08/06/2024)</td><td>$26.57</td></tr><tr><td>Alector Inc (ALEC.O)</td><td>U (11/26/2024)</td><td>$2.40</td></tr><tr><td>argenx SE (ARGX.O)</td><td>O (07/02/2025)</td><td>$707.96</td></tr><tr><td>Ax",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ca2453c7a2f6658a",
        "value": 707.96,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>U (11/26/2024)</td><td>$2.40</td></tr><tr><td>argenx SE (ARGX.O)</td><td>O (07/02/2025)</td><td>$707.96</td></tr><tr><td>Axsome Therapeutics (AXSM.O)</td><td>O (04/29/2024)</td><td>$121.86</td></t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "f461236ca0169a63",
        "value": 121.86,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2025)</td><td>$707.96</td></tr><tr><td>Axsome Therapeutics (AXSM.O)</td><td>O (04/29/2024)</td><td>$121.86</td></tr><tr><td>BeOne Medicines (ONC.O)</td><td>O (12/02/2024)</td><td>$300.14</td></tr><tr",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ddc6d7f1305df2b8",
        "value": 300.14,
        "unit": "$",
        "metric_type": "currency",
        "context": "04/29/2024)</td><td>$121.86</td></tr><tr><td>BeOne Medicines (ONC.O)</td><td>O (12/02/2024)</td><td>$300.14</td></tr><tr><td>Biomarin Pharmaceutical Inc (BMRN.O)</td><td>O (07/02/2025)</td><td>$58.66<",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ae058686de3dbcd9",
        "value": 58.66,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$300.14</td></tr><tr><td>Biomarin Pharmaceutical Inc (BMRN.O)</td><td>O (07/02/2025)</td><td>$58.66</td></tr><tr><td>Centessa Pharmaceuticals, Inc (CNTA.O)</td><td>O (09/19/2024)</td><td>$16.65",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "148724094240d2c3",
        "value": 16.65,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$58.66</td></tr><tr><td>Centessa Pharmaceuticals, Inc (CNTA.O)</td><td>O (09/19/2024)</td><td>$16.65</td></tr><tr><td>Certara Inc (CERT.O)</td><td>E (01/05/2021)</td><td>$10.97</td></tr><tr><td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "9ba0dc53003524c5",
        "value": 10.97,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (09/19/2024)</td><td>$16.65</td></tr><tr><td>Certara Inc (CERT.O)</td><td>E (01/05/2021)</td><td>$10.97</td></tr><tr><td>CG Oncology (CGON.O)</td><td>O (02/19/2024)</td><td>$26.48</td></tr><tr><td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "9a4a04b3e94cd7ab",
        "value": 26.48,
        "unit": "$",
        "metric_type": "currency",
        "context": ">E (01/05/2021)</td><td>$10.97</td></tr><tr><td>CG Oncology (CGON.O)</td><td>O (02/19/2024)</td><td>$26.48</td></tr><tr><td>Contineum Therapeutics (CTNM.O)</td><td>O (04/30/2024)</td><td>$10.01</td></",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "04277709c803a745",
        "value": 10.01,
        "unit": "$",
        "metric_type": "currency",
        "context": "024)</td><td>$26.48</td></tr><tr><td>Contineum Therapeutics (CTNM.O)</td><td>O (04/30/2024)</td><td>$10.01</td></tr><tr><td>Cullinan Therapeutics (CGEM.O)</td><td>O (03/06/2025)</td><td>$7.93</td></tr",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "e0f1c094e9524674",
        "value": 7.93,
        "unit": "$",
        "metric_type": "currency",
        "context": "2024)</td><td>$10.01</td></tr><tr><td>Cullinan Therapeutics (CGEM.O)</td><td>O (03/06/2025)</td><td>$7.93</td></tr><tr><td>Denali Therapeutics Inc (DNLI.O)</td><td>O (03/06/2025)</td><td>$15.60</td></",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "c7f34da0ed487148",
        "value": 15.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "025)</td><td>$7.93</td></tr><tr><td>Denali Therapeutics Inc (DNLI.O)</td><td>O (03/06/2025)</td><td>$15.60</td></tr><tr><td>Disc Medicine Inc (IRON.O)</td><td>O (11/04/2024)</td><td>$59.95</td></tr><t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "58826d144148f766",
        "value": 59.95,
        "unit": "$",
        "metric_type": "currency",
        "context": "/06/2025)</td><td>$15.60</td></tr><tr><td>Disc Medicine Inc (IRON.O)</td><td>O (11/04/2024)</td><td>$59.95</td></tr><tr><td>Erasca, Inc. (ERAS.O)</td><td>E (08/17/2025)</td><td>$1.58</td></tr><tr><td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7c2cbd6fee26249f",
        "value": 1.58,
        "unit": "$",
        "metric_type": "currency",
        "context": "O (11/04/2024)</td><td>$59.95</td></tr><tr><td>Erasca, Inc. (ERAS.O)</td><td>E (08/17/2025)</td><td>$1.58</td></tr><tr><td>Exelixis Inc. (EXEL.O)</td><td>O (01/26/2025)</td><td>$38.51</td></tr><tr><td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7badd84895e35e69",
        "value": 38.51,
        "unit": "$",
        "metric_type": "currency",
        "context": "E (08/17/2025)</td><td>$1.58</td></tr><tr><td>Exelixis Inc. (EXEL.O)</td><td>O (01/26/2025)</td><td>$38.51</td></tr><tr><td>Halozyme Therapeutics, Inc (HALO.O)</td><td>O (08/05/2025)</td><td>$73.18</t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "903912d3ced00216",
        "value": 73.18,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$38.51</td></tr><tr><td>Halozyme Therapeutics, Inc (HALO.O)</td><td>O (08/05/2025)</td><td>$73.18</td></tr><tr><td>Immunocore Holdings Ltd (IMCR.O)</td><td>E (12/12/2024)</td><td>$32.65</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "e41964381ce24665",
        "value": 32.65,
        "unit": "$",
        "metric_type": "currency",
        "context": "25)</td><td>$73.18</td></tr><tr><td>Immunocore Holdings Ltd (IMCR.O)</td><td>E (12/12/2024)</td><td>$32.65</td></tr><tr><td>Neurocrine Biosciences Inc (NBIX.O)</td><td>O (03/06/2025)</td><td>$138.13</",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "2432e716ab968b31",
        "value": 138.13,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$32.65</td></tr><tr><td>Neurocrine Biosciences Inc (NBIX.O)</td><td>O (03/06/2025)</td><td>$138.13</td></tr><tr><td>Recursion Pharmaceuticals Inc (RXRX.O)</td><td>E (05/22/2023)</td><td>$4.89",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "a0f4ca023309c7fc",
        "value": 4.89,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>$138.13</td></tr><tr><td>Recursion Pharmaceuticals Inc (RXRX.O)</td><td>E (05/22/2023)</td><td>$4.89</td></tr><tr><td>Schrodinger Inc. (SDGR.O)</td><td>E (11/19/2021)</td><td>$19.79</td></tr><tr>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "0362eecbba7beb0e",
        "value": 19.79,
        "unit": "$",
        "metric_type": "currency",
        "context": "05/22/2023)</td><td>$4.89</td></tr><tr><td>Schrodinger Inc. (SDGR.O)</td><td>E (11/19/2021)</td><td>$19.79</td></tr><tr><td>Terence C Flynn, Ph.D.</td><td></td><td></td></tr><tr><td>Alumis Inc. (ALMS.",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "e064ccb177224aa2",
        "value": 4.92,
        "unit": "$",
        "metric_type": "currency",
        "context": "Flynn, Ph.D.</td><td></td><td></td></tr><tr><td>Alumis Inc. (ALMS.O)</td><td>O (05/30/2025)</td><td>$4.92</td></tr><tr><td>Amgen Inc. (AMGN.O)</td><td>E (10/16/2023)</td><td>$287.97</td></tr><tr><td>A",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "31f84c7a7eee534d",
        "value": 287.97,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>O (05/30/2025)</td><td>$4.92</td></tr><tr><td>Amgen Inc. (AMGN.O)</td><td>E (10/16/2023)</td><td>$287.97</td></tr><tr><td>Arcus Biosciences Inc. (RCUS.N)</td><td>O (10/11/2022)</td><td>$10.56</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "aa6cec59076cb4d0",
        "value": 10.56,
        "unit": "$",
        "metric_type": "currency",
        "context": "23)</td><td>$287.97</td></tr><tr><td>Arcus Biosciences Inc. (RCUS.N)</td><td>O (10/11/2022)</td><td>$10.56</td></tr><tr><td>Arvinas Inc (ARVN.O)</td><td>E (04/06/2022)</td><td>$8.08</td></tr><tr><td>B",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "4e5ebd1b7793b7ae",
        "value": 8.08,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (10/11/2022)</td><td>$10.56</td></tr><tr><td>Arvinas Inc (ARVN.O)</td><td>E (04/06/2022)</td><td>$8.08</td></tr><tr><td>Biogen Inc (BIIB.O)</td><td>E (10/31/2024)</td><td>$136.36</td></tr><tr><td>B",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "6bb4657272656d0e",
        "value": 136.36,
        "unit": "$",
        "metric_type": "currency",
        "context": "td>E (04/06/2022)</td><td>$8.08</td></tr><tr><td>Biogen Inc (BIIB.O)</td><td>E (10/31/2024)</td><td>$136.36</td></tr><tr><td>Biohaven Ltd (BHVN.N)</td><td>O (07/24/2024)</td><td>$15.60</td></tr><tr><t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "c75beb2bfedb4383",
        "value": 15.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "(10/31/2024)</td><td>$136.36</td></tr><tr><td>Biohaven Ltd (BHVN.N)</td><td>O (07/24/2024)</td><td>$15.60</td></tr><tr><td>BioNTech SE (BNTX.O)</td><td>O (09/23/2024)</td><td>$103.01</td></tr><tr><td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "caf00b04c7580028",
        "value": 103.01,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (07/24/2024)</td><td>$15.60</td></tr><tr><td>BioNTech SE (BNTX.O)</td><td>O (09/23/2024)</td><td>$103.01</td></tr><tr><td>C4 Therapeutics (CCCC.O)</td><td>E (11/06/2023)</td><td>$2.58</td></tr><tr>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7333cc7716fd88eb",
        "value": 2.58,
        "unit": "$",
        "metric_type": "currency",
        "context": "9/23/2024)</td><td>$103.01</td></tr><tr><td>C4 Therapeutics (CCCC.O)</td><td>E (11/06/2023)</td><td>$2.58</td></tr><tr><td>CRISPR Therapeutics AG (CRSP.O)</td><td>U (10/11/2022)</td><td>$53.53</td></t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "0d95565449b0d453",
        "value": 34.72,
        "unit": "$",
        "metric_type": "currency",
        "context": "<table><tr><td>Legend Biotech Corp (LEGN.O)</td><td>O (01/31/2022)</td><td>$34.72</td></tr><tr><td>Moderna Inc (MRNA.O)</td><td>E (12/16/2020)</td><td>$25.10</td></tr><tr><td>Nurix",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "f367953a9593ba86",
        "value": 25.1,
        "unit": "$",
        "metric_type": "currency",
        "context": ">O (01/31/2022)</td><td>$34.72</td></tr><tr><td>Moderna Inc (MRNA.O)</td><td>E (12/16/2020)</td><td>$25.10</td></tr><tr><td>Nurix Therapeutics Inc. (NRIX.O)</td><td>E (10/11/2022)</td><td>$9.55</td></",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "08cc53baf8625c3e",
        "value": 9.55,
        "unit": "$",
        "metric_type": "currency",
        "context": "20)</td><td>$25.10</td></tr><tr><td>Nurix Therapeutics Inc. (NRIX.O)</td><td>E (10/11/2022)</td><td>$9.55</td></tr><tr><td>Prime Medicine Inc (PRME.O)</td><td>E (11/14/2022)</td><td>$3.43</td></tr><tr",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "ea731296f14c2761",
        "value": 3.43,
        "unit": "$",
        "metric_type": "currency",
        "context": "/11/2022)</td><td>$9.55</td></tr><tr><td>Prime Medicine Inc (PRME.O)</td><td>E (11/14/2022)</td><td>$3.43</td></tr><tr><td>Regeneron Pharmaceuticals Inc. (REGN.O)</td><td>O (09/09/2022)</td><td>$586.9",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "e9b14601bafb99bd",
        "value": 586.96,
        "unit": "$",
        "metric_type": "currency",
        "context": "d><td>$3.43</td></tr><tr><td>Regeneron Pharmaceuticals Inc. (REGN.O)</td><td>O (09/09/2022)</td><td>$586.96</td></tr><tr><td>Structure Therapeutics Inc (GPCR.O)</td><td>O (09/22/2024)</td><td>$19.00</",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "fd6534e174e761b3",
        "value": 19.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$586.96</td></tr><tr><td>Structure Therapeutics Inc (GPCR.O)</td><td>O (09/22/2024)</td><td>$19.00</td></tr><tr><td>United Therapeutics Corp (UTHR.O)</td><td>E (07/11/2024)</td><td>$305.35</td",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "815594c3fd97a15c",
        "value": 305.35,
        "unit": "$",
        "metric_type": "currency",
        "context": "4)</td><td>$19.00</td></tr><tr><td>United Therapeutics Corp (UTHR.O)</td><td>E (07/11/2024)</td><td>$305.35</td></tr><tr><td>Vertex Pharmaceuticals (VRTX.O)</td><td>E (05/03/2022)</td><td>$389.08</td>",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "26504c323edc7ff1",
        "value": 389.08,
        "unit": "$",
        "metric_type": "currency",
        "context": "24)</td><td>$305.35</td></tr><tr><td>Vertex Pharmaceuticals (VRTX.O)</td><td>E (05/03/2022)</td><td>$389.08</td></tr></table> Stock Ratings are subject to change. Please see latest research for each c",
        "provenance": {
          "page": 10
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 3,
      "tables_count": 0,
      "numerical_data_count": 107,
      "passages_count": 75,
      "entities_count": 20
    }
  }
}